Fineline Cube

Follow:
14436 Articles
Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia
CompanyDrug

Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia

Merck KGaA Partners with Roche to Commercialize Tepmetko in China
CompanyDeals

Merck KGaA Partners with Roche to Commercialize Tepmetko in China

China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
CompanyHospital

China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge

GSK's Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections
CompanyDrug

GSK’s Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections

Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
CompanyDrug

Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes

WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
Company

WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services

Sanofi's Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis
CompanyDrug

Sanofi’s Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis

Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
Company

Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment

Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
Company

Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability

China's 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation
Policy / Regulatory

China’s 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation

Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
Company

Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab

Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial
CompanyDrug

Shanghai Henlius Biotech Receives NMPA Approval for HLX79 in Glomerulonephritis Trial